E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Lupus Nephritis |
Nefritis lúpica |
|
E.1.1.1 | Medical condition in easily understood language |
Lupus Nephritis |
Nefritis lúpica |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025140 |
E.1.2 | Term | Lupus nephritis |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis. |
El objetivo de este estudio es evaluar la eficacia, seguridad y tolerabilidad de belimumab en pacientes adultos con nefritis lúpica activa |
|
E.2.2 | Secondary objectives of the trial |
not applicable |
No aplicable |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Title: Pharmacogenetic Research Date: 08 March 2012 Objectives: -Relationship between genetic variants and the pharmacokinetics of belimumab. - Relationship between genetic variants and safety and/or tolerability of belimumab. - Relationship between genetic variants and efficacy of belimumab. |
Título: Estudio farmacogenético Fecha 8 de marzo de 2012 Objetivos: - Relación entre las diferentes variantes genéticas y la farmacocinética del belimumab - Relación entre las diferentes variantes genéticas y la seguridad y/o tolarabilidad del belimumab - Relación entre las diferentes variantes genéticas y la eficacia del belimumab. |
|
E.3 | Principal inclusion criteria |
-Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria. -Biopsy confirmed active lupus nephritis. -Autoantibody-positive. |
- Tener un diagnóstico clínico de lupus eritematoso sistémico (LES) con arreglo a los criterios del American College of Rheumatology (ACR) - Presentar una nefritis lúpica proliferativa, confirmada mediante biopsia - Tener unos resultados inequívocamente positivos en los análisis de anticuerpos antinucleares |
|
E.4 | Principal exclusion criteria |
-Pregnant or nursing. -On dialysis within the past year. -Prior treatment with belimumab. -Receipt of any induction therapy within the past 6 months. -Receipt of any B cell targeted therapy (for example, rituximab), investigational biological agent within the past year. -Severe active central nervous system (CNS) lupus. -Required management of acute or chronic infections within the past 60 days. -Current drug or alcohol abuse or dependence. -Tested positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. -History of severe allergic reaction to contrast agents or biological medicines. |
- Mujer embarazada o en período de lactancia - En diálisis durante el pasado año - Haber recibido un tratamiento previo con belimumab - Haber recibido una terapia de inducción durante los últimos 6 meses - Haber recibido una terapia dirigido contra células B (por ejemplo, rituximab) durante el último año. - Presentar un lupus activo grave con afectación del sistema nervioso central (SNC) - Haber requerido tratamiento por infecciones agudas o crónicas en los últimos 60 días - Presencia o antecedentes de abuso o dependencia de drogas o alcohol - Tener una prueba positiva en el pasado o en la selección para anticuerpos contra el VIH, antígeno de superficie del virus de la hepatitis B o anticuerpos contra el virus de la hepatitis C. - Tener antecedentes de una reacción anafiláctica a la administración parenteral de medios de contraste, proteínas humanas o murinas o anticuerpos monoclonales. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Outcome Measure: -Number of participants with a renal response at Week 104 |
Criterio de valoración primario: - Número de sujetos con respuesta renal a la semana 104 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Please refer to point E.5.1 |
Por favor, referirse al punto E.5.1 |
|
E.5.2 | Secondary end point(s) |
Secondary Outcome Measures: - Number of participants with a complete renal response at Week 104 - Number of participants with a renal response at Week 52 - Number of participants who experienced adverse events up to 136 weeks |
Criterios de valoración secundarios: - Número de sujetos con respuesta renal completa a la semana 104 -Número de sujetos con respuesta renal a la semana 52 -Número de sujetos que experimentaron acontecimientos adversos en las 136 semanas |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please refer to point E.5.2 |
Por favor, referirse al punto E.5.2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Belgium |
Brazil |
Canada |
Colombia |
France |
Germany |
Hungary |
India |
Korea, Republic of |
Mexico |
Philippines |
Russian Federation |
Spain |
Taiwan |
Thailand |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit |
Última visita, último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |